Core Insights - Intuitive Surgical has a strong market presence with over 11,100 da Vinci surgical robots installed globally, generating approximately 75% of its revenue from services and sales of instruments and accessories, creating a recurring revenue stream [2] - The company currently has a high price-to-earnings (P/E) ratio of 64, indicating strong market expectations for future growth [1] - Medtronic has recently received FDA approval for its Hugo surgical robot, marking its entry into the U.S. market, with the first surgeries performed in February [4] Company Analysis - Intuitive Surgical's da Vinci system has established a significant foothold in the surgical robotics market, but competition is increasing, with Medtronic emerging as a notable player [4] - Medtronic's P/E ratio stands at 27, which is lower than that of Intuitive Surgical, suggesting potential for valuation growth if the Hugo system achieves similar success as the da Vinci system [5] - Medtronic's business is more diversified across various medical sectors, which may limit the growth potential of the Hugo system compared to Intuitive Surgical's focused approach [7] Investment Considerations - Medtronic offers a dividend yield of approximately 2.9%, appealing to dividend investors, while Intuitive Surgical does not provide dividends [8] - The market is currently in a cautious phase regarding Medtronic's new product developments, but the introduction of the Hugo system could change investor sentiment [7]